Are Clinical Sites Seeing Cost Reductions As A Result Of DCTs?

When the COVID-19 pandemic hit the U.S. in March 2020, many drug developers were caught by surprise. With clinics overwhelmed by COVID patients and the reluctance of some patients to venture out to those clinics, many trials faced the prospect of being delayed or canceled. Decentralized clinical trials (DCTs) and hybrid trials, which can take studies from the clinics to the patients, seemed to be the solution to keep things on track.

But where do your sites stand on DCTs? Do they fully understand what they are and how they will impact the financial landscape? Are they a blessing or a curse to site personnel? In August 2022 Clinical Leader Live featured three site experts who were able to discuss the pain points of DCTs, including costs, budgeting, training, support, staffing, resources, and more.

In this segment, Karri Venn, COO, president, and chair of the operating board at Centricity Research, and Brad Hightower, CEO of Hightower Clinical, discuss the cost benefits of DCTs and what sites are seeing in terms of expense reductions.